To what degree is late life cognitive decline driven by age-related neuropathologies?
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The ageing brain is vulnerable to a wide array of neuropathologies. Prior work estimated that the three most studied of these, Alzheimer’s disease, infarcts, and Lewy bodies, account for ∼40% of the variation in late life cognitive decline. However, that estimate did not incorporate many other diseases that are now recognized as potent drivers of cognitive decline [e.g. limbic predominant age-related TDP-43 encephalopathy (LATE-NC), hippocampal sclerosis, other cerebrovascular conditions]. We examined the degree to which person-specific cognitive decline in old age is driven by a wide array of neuropathologies. Deceased participants (n = 1164) from two longitudinal clinical-pathological studies, the Rush Memory and Aging Project and Religious Orders Study, completed up to 24 annual evaluations including 17 cognitive performance tests and underwent brain autopsy. Neuropathological examinations provided 11 pathological indices, including markers of Alzheimer’s disease, non- Alzheimer’s disease neurodegenerative diseases (i.e. LATE-NC, hippocampal sclerosis, Lewy bodies), and cerebrovascular conditions (i.e. macroscopic infarcts, microinfarcts, cerebral amyloid angiopathy, atherosclerosis, and arteriolosclerosis). Mixed effects models examined the linear relation of pathological indices with global cognitive decline, and random change point models examined the relation of the pathological indices with the onset of terminal decline and rates of preterminal and terminal decline. Cognition declined an average of about 0.10 unit per year (estimate = −0.101, SE = 0.003, P < 0.001) with considerable heterogeneity in rates of decline (variance estimate for the person-specific slope of decline was 0.0094, P < 0.001). When considered separately, 10 of 11 pathological indices were associated with faster decline and accounted for between 2% and 34% of the variation in decline, respectively. When considered simultaneously, the 11 pathological indices together accounted for 43% of the variation in decline; Alzheimer’s disease-related indices accounted for 30–36% of the variation, non-Alzheimer’s disease neurodegenerative indices 4–10%, and cerebrovascular indices 3–8%. Finally, the 11 pathological indices combined accounted for less than a third of the variation in the onset of terminal decline (28%) and rates of preterminal (32%) and terminal decline (19%). Although age-related neuropathologies account for a large proportion of the variation in late life cognitive decline, considerable variation remains unexplained even after considering a wide array of neuropathologies. These findings highlight the complexity of cognitive ageing and have important implications for the ongoing effort to develop effective therapeutics and identify novel treatment targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“Neuropathologies can accumulate years or even decades prior to cognitive impairment, but their prevalence increases dramatically with advancing age, with one or more pathologies evident in many individuals over the age of 60 and nearly all over 80.(1,6,7) Moreover, distinct diseases contribute to particular manifestat…”
BackgroundLimbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Self-citationReligious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
Self-citationTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916
Individual differences in rates of change in cognitive abilities of older persons.
Wilson, R. S., Beckett, L. A., Barnes, L. L., Schneider, J. A., Bach, J., Evans, D. A., & Bennett, D. A. (2002) · Psychology and Aging · doi:10.1037/0882-7974.17.2.179 · Cited by 842 · cited 1×
“The use of a composite score minimizes floor and ceiling effects and other sources of random variability and is optimal for studies examining change in cognition over many years.(12,14,16,17)”
MethodSelf-citationArvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30029-1 · Cited by 581
Self-citationPerson-specific contribution of neuropathologies to cognitive loss in old age
Boyle, P. A., Yu, L., Wilson, R. S., Leurgans, S. E., Schneider, J. A., & Bennett, D. A. (2018) · Annals of Neurology · doi:10.1002/ana.25123 · Cited by 508 · cited 1×
“Moreover, to complicate matters further, the impact of any given pathology at a person-specific level varies depending on the specific combination of other neuropathologies present.(11) Thus, it is clear that disease-modifying therapies for Alzheimer’s disease in particular are urgently needed, but with so many other…”
BackgroundSelf-citationCerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease
Esiri, M. M., Nagy, Z., Smith, M. Z., Barnetson, L., & Smith, A. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02355-7 · Cited by 493
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481
Much of late life cognitive decline is not due to common neurodegenerative pathologies
Boyle, P. A., Wilson, R. S., Yu, L., Barr, A. M., Honer, W. G., Schneider, J. A., & Bennett, D. A. (2013) · Annals of Neurology · doi:10.1002/ana.23964 · Cited by 323 · cited 4×
“We previously reported that pathological indices of Alzheimer’s disease, infarcts, and Lewy bodies accounted for 40% of the person-specific variation in late life cognitive decline.(12) However, it is now clear that several other age-related neuropathologies also are important drivers of late life cognitive decline.”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Mathys, H., Peng, Z., Boix, C. A., Victor, M. B., Leary, N., Babu, S., Abdelhady, G., Jiang, X., Ng, A. P., Ghafari, K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.039 · Cited by 495
“84, 92, 74”
Self-citationAlzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease
Arenaza‐Urquijo, E. M., Boyle, R., Casaletto, K., Anstey, K. J., Vila‐Castelar, C., Colverson, A., Palpatzis, E., Eissman, J. M., Kheng Siang Ng, T., Raghavan, S., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13844 · Cited by 223
“219 Figure 5 shows a framework in which AD pathologies, risk/protective factors (reviewed above), and non-AD pathologies are associated with cognitive resilience through their association with brain structure and function (brain resilience).”
Cellular communities reveal trajectories of brain ageing and Alzheimer’s disease
Green, G. S., Fujita, M., Yang, H.-S., Taga, M., Cain, A., McCabe, C., Comandante-Lou, N., White, C. C., Schmidtner, A. K., Zeng, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07871-6 · Cited by 204
Self-citationLATE-NC staging in routine neuropathologic diagnosis: an update
Nelson, P. T., Lee, E. B., Cykowski, M. D., Alafuzoff, I., Arfanakis, K., Attems, J., Brayne, C., Corrada, M. M., Dugger, B. N., Flanagan, M. E., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-022-02524-2 · Cited by 176
“For example, in an attributable risk analysis based on all observed pathologic changes that may contribute to cognitive impairment in a large community cohort, LATE-NC accounted for more than 15% of identified amnestic dementia risk [16, 114].”
Self-citationGranzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
Association of dementia risk with focal epilepsy and modifiable cardiovascular risk factors
Tai, X. Y., Torzillo, E., Lyall, D. M., Manohar, S., Husain, M., & Sen, A. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0339 · Cited by 61
Once upon a time, the Amyloid Cascade Hypothesis
Granzotto, A., & Sensi, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102161 · Cited by 57
“Furthermore, statistical modeling suggests that this mixed-neuropathology accounts only for a small fraction of the cognitive decline, with at least fifty percent of the variation in cognitive decline remaining unexplained (Boyle et al., 2021).”
Green, G. S., Yang, H., Fujita, M., Taga, M., Regev, A., Menon, V., Bennett, D. A. A., Habib, N., & De Jager, P. L. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.083212 · Cited by 51
Self-citationGreen, G. S., Fujita, M., Yang, H.-S., Taga, M., McCabe, C., Cain, A., White, C. C., Schmidtner, A. K., Zeng, L., Wang, Y., et al. (2023) · doi:10.1101/2023.03.07.531493 · Cited by 51
Self-citationAsken, B. M., Tanner, J. A., VandeVrede, L., Mantyh, W. G., Casaletto, K. B., Staffaroni, A. M., La Joie, R., Iaccarino, L., Soleimani-Meigooni, D., Rojas, J. C., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200678 · Cited by 40
Trends in postmortem neurodegenerative and cerebrovascular neuropathologies over 25 years
Grodstein, F., Leurgans, S. E., Capuano, A. W., Schneider, J. A., & Bennett, D. A. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5416 · Cited by 41
Self-citationBrain microRNAs differentially expressed in age-related cerebral pathologies
Luo, T., Vattathil, S. M., Lori, A., Schneider, J. A., Bennett, D. A., Wingo, T. S., & Wingo, A. P. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.03.014 · Cited by 6
Self-citationZammit, A. R., Klein, H.-U., Yu, L., Levey, A. I., Seyfried, N. T., Wingo, A. P., Wingo, T. S., Schneider, J. A., Bennett, D. A., & Buchman, A. S. (2024) · Neurology · doi:10.1212/wnl.0000000000207816 · Cited by 6
Self-citationEarly neuronal reprogramming and cell cycle reentry shape Alzheimer’s disease progression
Meir, R., Schwartz, G., Adam, M., Lapidot, A. A., Cain, A., Green, G. S., Menon, V., Bennett, D. A., De Jager, P. L., & Habib, N. (2025) · doi:10.1101/2025.06.04.653670 · Cited by 3
Self-citation
Metadata
- Authors
- Boyle, P. A., Wang, T., Yu, L., Wilson, R. S., Dawe, R., Arfanakis, K., Schneider, J. A., & Bennett, D. A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-20
- Volume
- 144
- Issue
- 7
- Pages
- 2166-2175
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W3138260811
- Cited by
- 219
- References
- 20
- FWCI
- 21.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.